Oklahoma Specialized Center of Research in SLE

描述（由申请人提供）：俄克拉荷马州医学研究基金会提出了一个系统性红斑狼疮的专门研究中心（SCOR），该中心将专注于了解自身抗体在SLE中的作用。该中心的总体目标是将临床风湿性疾病研究与整个校园的基础科学研究人员相结合，从而加强该州的基础科学和以患者为导向的研究。Morris Reichlin博士是主任，他为这个新的综合项目带来了风湿性疾病研究活动的杰出职业价值。简而言之，这个SCOR有五个关键的研究人员，五个合作研究人员（州内），五个合作研究人员（州外），九个额外的关节炎研究人员，十四个基础科学研究人员，一个数据和分析核心主任，咨询委员会和一系列兼职教师，博士后研究员，临床研究员，MD-博士生和研究生。 该提案的关键项目包括各种方法来了解SLE中自身免疫反应如何开始以及自身抗体如何导致发病机制。本SCOR的主要项目将侧重于了解与症状和SLE疾病发作相关的自身抗体的发展，探索自身抗体在血脂异常和加速性心脏病发展中的作用，评估B细胞耐受性在狼疮自身抗体积累中的基本作用，确定这些异常自身免疫反应的潜在病因学触发因素，并评估严重血清学和临床SLE表型的遗传易感性。一个数据和分析核心和行政核心将支持这些单独的项目。 俄克拉荷马州SLE SCOR的主要目标有四个方面。首先，该SCOR将通过支持上述研究项目，通过基础和临床科学的整合加强研究，以找到SLE的关键病因。第二，生物统计/研究设计问题将纳入所有正在进行的风湿病研究，以提高目前的研究活动水平。第三，关键的独特患者资源将由几个项目共享。最后，这个SCOR将提供一个多学科的结构和资源，通过参与心血管生物学，狼疮遗传学，炎症，凝血，分子生物学，免疫生物学，免疫遗传学，临床药理学和蛋白质研究的强大基础科学家的影响，加强当前的临床风湿性疾病研究。

DESCRIPTION (provided by applicant): The Oklahoma Medical Research Foundation proposes a Specialized Center of Research (SCOR) in systemic lupus erythematosus which will focus on understanding the roles of autoantibodies in SLE. The overarching goal of this center will be to integrate clinical rheumatic disease research with basic science investigators from throughout campus thereby strengthening basic science and patient oriented research in this state. Dr. Morris Reichlin is the Director, and he brings a distinguished career's worth of rheumatic disease research activities to this new integrated program. Briefly, this SCOR has five key investigators, five collaborating investigators (in-state), five collaborating investigators (out-of-state), nine additional arthritis investigators, fourteen basic science investigators, a Data and Analysis Core Director, Advisory Committee and a host of adjunct faculty, post-doctoral fellows, clinical fellows, MD-PhD students and graduate students. The key projects for this proposal include various approaches to understand how autoimmune responses start in SLE and how autoantibodies could lead to pathogenesis. The major projects in this SCOR will focus on understanding the development of autoantibodies with regards to symptom and SLE disease onset, exploring the role of autoantibodies in the development of dyslipidemias and accelerated cardiac disease, evaluating the basic role of B cell tolerance in the accrual of lupus autoantibodies, identifying potential etiologic triggers of these aberrant autoimmune responses and assessing the genetic predisposition to a severe serological and clinical SLE phenotype. A Data and Analysis Core and Administrative Core will support each of these individual projects. The primary Oklahoma SLE SCOR objectives are fourfold. First, this SCOR will strengthen research through integration of basic and clinical science in finding key etiological factors for SLE by supporting the above mentioned research projects. Second, biostatistical/research design issues will be incorporated into all ongoing rheumatic disease research in order to raise the current level of research activity. Third, key unique patient resources will be shared by several of the projects. Finally, this SCOR will provide a multidisciplinary structure and resources to strengthen current clinical rheumatic disease research through the influence of strong basic scientists involved in cardiovascular biology, lupus genetics, inflammation, coagulation, molecular biology, immunobiology, immunogenetics, clinical pharmacology and protein studies.